Amgen Inc

Amgen insider trading snapshot: CTO David Reese sold 6,022 shares at $366.21. Routine equity program, no change in confidence—portfolio rebalancing, not a red flag.

Amgen insider sale by EVP & Gen. Counsel Graham Jonathan P shows routine trading, not a confidence dip; stock remains strong amid pipeline growth.

Amgen insider Santos Esteban sells 5,621 shares at $366.21—no panic signal, just routine liquidity; executives stay invested, signaling long‑term confidence.

Amgen insider Busch sells 327 shares at $366.21—routine vesting, not a red flag, reinforcing long‑term confidence in the company’s pipeline.

Amgen insider sales reveal a strategic realignment: modest, liquidity‑driven trades amid broader executive buying, signaling confidence in future growth.

Bradway’s $156.35 Amgen buy shows insider confidence at a discount, hinting at value for long‑term biotech investors.

Amgen insiders keep buying shares, boosting investor confidence amid biotech resilience—learn why execs are adding stake and what it means for your portfolio.

Amgen insider buying signals confidence: EVP Santos Esteban & top execs pile up shares amid a 13% YTD gain and 52‑week high, hinting at strong pipeline prospects.

Amgen insider buying spikes: EVP & General Counsel Graham P. purchases 10,723 shares, signaling long‑term confidence amid a quiet quarter, boosting investor optimism.

Amgen EVP Santos Esteban’s sizable share purchase signals strong management confidence and could hint at upcoming product approvals, boosting investor optimism.